Precigen Inc (OQ:PGEN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Tel: N/A
IR: See website
Key People
Randal Joe Kirk
Executive Chairman of the Board
Helen Sabzevari
President, Chief Executive Officer, President - Precigen, Inc.
Rick L. Sterling
Chief Financial Officer
Jeffrey T. Perez
Senior Vice President - Intellectual Property Affairs
Donald P. Lehr
Chief Legal Officer
Business Overview
Precigen, Inc., formerly Intrexon Corporation, forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.
Financial Overview
For the three months ended 31 March 2020, Precigen Inc revenues increased 32% to $29.8M. Net loss before extraordinary items decreased 42% to $29.9M. Revenues reflect Collaboration and licensing revenues increase of 80% to $10.7M, Service revenues increase of 23% to $13.9M, Product revenues increase of 3% to $5M. Lower net loss reflects Research and development - Balancing val decrease of 28% to $18.3M (expense).
Employees: 770 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $635.29M as of Mar 31, 2020
Annual revenue (TTM): $97.23M as of Mar 31, 2020
EBITDA (TTM): -$121.80M as of Mar 31, 2020
Net annual income (TTM): -$175.40M as of Mar 31, 2020
Free cash flow (TTM): -$149.95M as of Mar 31, 2020
Net Debt Last Fiscal Year: $72.65M as of Mar 31, 2020
Shares outstanding: 171,014,250 as of Apr 30, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization